Literature DB >> 19454086

Depression in adults: drug and physical treatments.

Corrado Barbui1, Rob Butler, Andrea Cipriani, John Geddes, Simon Hatcher.   

Abstract

INTRODUCTION: Depression may affect up to 10% of the population, with half of affected people having recurrence of their symptoms. In mild to moderate depression, there is no reliable evidence that any one treatment is superior in improving symptoms of depression, but the strength of evidence supporting different treatments varies. In severe depression, only prescription antidepressants and electroconvulsive therapy are known to improve symptoms. METHODS AND
OBJECTIVES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments in mild to moderate and severe depression, and in treatment-resistant depression? Which interventions reduce relapse rates? We searched: Medline, Embase, The Cochrane Library and other important databases up to April 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 87 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antidepressant drugs (tricyclic antidepressants [including low-dose tricyclic antidepressants], selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, reboxetine, or venlafaxine), continuing prescription antidepressant drugs, electroconvulsive therapy, exercise, lithium augmentation, pindolol augmentation, St John's Wort.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19454086      PMCID: PMC2943802     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  87 in total

Review 1.  Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials.

Authors:  Dean Fergusson; Steve Doucette; Kathleen Cranley Glass; Stan Shapiro; David Healy; Paul Hebert; Brian Hutton
Journal:  BMJ       Date:  2005-02-19

2.  Venlafaxine for major depression.

Authors:  Andrea Cipriani; John R Geddes; Corrado Barbui
Journal:  BMJ       Date:  2007-02-03

3.  Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis.

Authors:  Gerald Gartlehner; Richard A Hansen; Timothy S Carey; Kathleen N Lohr; Bradley N Gaynes; Leah C Randolph
Journal:  Int Clin Psychopharmacol       Date:  2005-03       Impact factor: 1.659

4.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

5.  Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant.

Authors:  C Thompson; R C Peveler; D Stephenson; J McKendrick
Journal:  Am J Psychiatry       Date:  2000-03       Impact factor: 18.112

6.  Exercise treatment for depression: efficacy and dose response.

Authors:  Andrea L Dunn; Madhukar H Trivedi; James B Kampert; Camillia G Clark; Heather O Chambliss
Journal:  Am J Prev Med       Date:  2005-01       Impact factor: 5.043

7.  Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.

Authors:  Jeffrey S Simon; Loren M Aguiar; Nadia R Kunz; Dean Lei
Journal:  J Psychiatr Res       Date:  2004 May-Jun       Impact factor: 4.791

8.  Antidepressants and the risk of suicidal behaviors.

Authors:  Hershel Jick; James A Kaye; Susan S Jick
Journal:  JAMA       Date:  2004-07-21       Impact factor: 56.272

Review 9.  Pharmacokinetic interactions of drugs with St John's wort.

Authors:  Shufeng Zhou; Eli Chan; Shen-Quan Pan; Min Huang; Edmund J D Lee
Journal:  J Psychopharmacol       Date:  2004-06       Impact factor: 4.153

Review 10.  Amitriptyline for inpatients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis.

Authors:  C Barbui; G Guaiana; M Hotopf
Journal:  Pharmacopsychiatry       Date:  2004-05       Impact factor: 5.788

View more
  4 in total

Review 1.  Repetitive Transcranial Magnetic Stimulation for the Treatment of Resistant Depression: A Scoping Review.

Authors:  Medard Kofi Adu; Reham Shalaby; Pierre Chue; Vincent I O Agyapong
Journal:  Behav Sci (Basel)       Date:  2022-06-17

2.  Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model.

Authors:  Joakim Ramsberg; Christian Asseburg; Martin Henriksson
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

3.  Herba Rhodiolae alleviates depression via the BDNF/TrkB-GSK-3β signaling pathway.

Authors:  Lili Gao; Chenghan Wu; Yuansheng Liao; Sheng Zhang; Jian Zhao
Journal:  Ann Transl Med       Date:  2021-12

4.  Ketamine as antidepressant? Current state and future perspectives.

Authors:  H W W Hasselmann
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.